Premium
Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia
Author(s) -
Unal Sule,
Kara Fehime,
Ozen Seza,
Orhan Diclehan,
Tuncer Murat,
Gumruk Fatma
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22469
Subject(s) - stanozolol , medicine , dermatology , pentoxifylline , pediatrics , surgery , primary prevention , disease , anabolism
Severe essential cryofibrinogenemia is rare in childhood, and both the diagnosis and the management are challenging for pediatricians. An 11‐year‐old male, who had already lost two digits following cold exposure, was referred after multiple visits to various hospitals and subsequently diagnosed as primary cryofibrinogenemia. His history revealed unresponsiveness to calcium channel blockers, acetyl salicylic acid, pentoxifylline, dextran, and steroids. Stanozolol (2 mg/day, orally) prophylaxis was initiated and no new skin lesions developed following starting this treatment. Some of the newly formed lesions at the onset of stanozolol healed. Pediatr Blood Cancer 2010;55:174–176. © 2010 Wiley‐Liss, Inc.